Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer
Metrics: PDF 1195 views | HTML 3065 views | ?
Ariadna Giró-Perafita1,*, Ariadna Sarrats1,*, Ferran Pérez-Bueno1,2, Glòria Oliveras1,3, Maria Buxó4, Joan Brunet1,3, Gemma Viñas1,3 and Teresa Puig Miquel1
1New Terapeutics Targets Laboratory (TargetsLab), Department of Medical Sciences, University of Girona, Girona, Spain
2Pathology Department, Dr. Josep Trueta Hospital and Catalan Institute of Health (ICS), Girona, Spain
3Medical Oncology Department, Catalan Institute of Oncology (ICO), Girona, Spain
4Girona Biomedical Research Institute (IDIBGI), Girona, Spain
*These authors have contributed equally to this work
Teresa Puig Miquel, email: [email protected]
Gemma Viñas, email: [email protected]
Keywords: EGFR, breast cancer molecular subtypes
Received: January 25, 2017 Accepted: May 05, 2017 Published: August 10, 2017
Triple-Negative Breast Cancer (TNBC) has poor prognosis and no approved targeted therapy. We previously showed that the enzyme fatty acid synthase (FASN) was largely expressed in a small TNBC patients’ cohort and its inhibition synergized with cetuximab in TNBC preclinical mouse models. Here, we evaluated FASN and EGFR expression in a cohort of TNBC patients and we study their prognostic role and their association with clinico-histopathological features, intrinsic TNBC subtypes and survival.
FASN, EGFR, CK5/6 and vimentin expression were retrospective evaluated by Immunohistochemistry in 100 primary TNBC tumors. FASN expression was classified into high and low FASN groups. EGFR, CK5/6 and vimentin expression were used in TNBC intrinsic subtypes classification.
FASN was expressed in most of the TNBC patients but did not correlate with overall survival or disease-free survival in this cohort. High FASN group was significantly associated with positive node status. FASN expression was significantly higher in Basal-Like patients than in Mesenchymal-Like ones. EGFR expression was positive in 50% of the tumors, and those patients showed poorer DFS. Altogether, our findings provide a rationale for further investigation the prognostic role of FASN and EGFR expression in a larger cohort of TNBC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.